{"id":42438,"date":"2025-09-29T09:07:07","date_gmt":"2025-09-29T09:07:07","guid":{"rendered":"https:\/\/www.europesays.com\/se\/42438\/"},"modified":"2025-09-29T09:07:07","modified_gmt":"2025-09-29T09:07:07","slug":"forskargrupp-vid-ki-sos-utvarderar-behandlingar-vid-syrebrist-i-benen","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/42438\/","title":{"rendered":"Forskargrupp vid KI S\u00d6S utv\u00e4rderar behandlingar vid syrebrist i benen"},"content":{"rendered":"<p>Vanlig behandling \u00e4r att vidga blodk\u00e4rlen med en ballong, ibland med hj\u00e4lp av ett litet metalln\u00e4t (stent). P\u00e5 senare \u00e5r har en ny teknik utvecklats d\u00e4r ballonger och stentar \u00e4r t\u00e4ckta med l\u00e4kemedel som ska minska risken f\u00f6r att k\u00e4rlen t\u00e4pps till igen. Men det har saknats tydliga vetenskapliga bevis f\u00f6r att tekniken verkligen fungerar b\u00e4ttre.<\/p>\n<p>De tv\u00e5 studierna \u2013\u00a0SWEDEPAD 1\u00a0och\u00a0SWEDEPAD 2\u00a0\u2013 unders\u00f6kte olika grupper av patienter:<\/p>\n<ul>\n<li>SWEDEPAD 1\u00a0fokuserade p\u00e5 patienter med allvarlig sjukdom och risk f\u00f6r amputation.<\/li>\n<li>SWEDEPAD 2\u00a0unders\u00f6kte patienter med lindrigare besv\u00e4r, fr\u00e4mst sm\u00e4rta vid g\u00e5ng (f\u00f6nstertittarsjuka).<\/li>\n<\/ul>\n<p>Totalt deltog 3 555 patienter fr\u00e5n 22 kliniker i Sverige. <a href=\"https:\/\/ki.se\/forskning\/forskningsomraden-centrum-och-natverk\/forskargrupper\/sosvasc-david-lindstroms-forskargrupp#tab-start\" data-entity-type=\"external\" rel=\"nofollow noopener\" target=\"_blank\">Forskargruppen k\u00e4rlkirurgi KIS\u00d6S<\/a> var n\u00e4st st\u00f6rst i landet och bidrog med 399 patienter. Patienterna lottades till att f\u00e5 antingen den nya tekniken med l\u00e4kemedelsbelagda produkter eller den traditionella behandlingen utan l\u00e4kemedel.\u00a0<\/p>\n<p>Resultaten visar att den nya tekniken inte minskade risken f\u00f6r amputation (SWEDEPAD 1) eller f\u00f6rb\u00e4ttrade livskvaliteten efter ett \u00e5r (SWEDEPAD 2). Det inneb\u00e4r att b\u00e5da behandlingarna \u00e4r likv\u00e4rdiga vilket har stor h\u00e4lsoekonomisk betydelse.<\/p>\n<p>Studierna \u00e4r publicerade i tidskriften\u00a0The Lancet\u00a0och har genomf\u00f6rts i samarbete med bland annat Sahlgrenska Universitetssjukhuset och G\u00f6teborgs Universitet.<\/p>\n<p>Publikationerna<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902617\/\" rel=\"nofollow noopener\" target=\"_blank\">Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial<\/a><br \/>Falkenberg M, James S, Andersson M, Andersson M, Delle M, Engstr\u00f6m J, Fransson T, Gillgren P, Hilbertson A, H\u00f6rer TM, Jacobsson E, Kragsterman B, Lindb\u00e4ck J, Lindgren H, Ludwigs K, Mellander S, Nelz\u00e9n O, Olin R, Sigvant B, Skoog P, Starck J, Tegler G, Thorbj\u00f8rnsen K, Truedson M, Wahlgren CM, Wallinder J, \u00d6jersj\u00f6 A, Nordanstig J; SWEDEPAD trial investigators. Lancet. 2025 Sep 13;406(10508):1103-1114. doi: 10.1016\/S0140-6736(25)01585-5. Epub 2025 Aug 31. PMID: 40902617.<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902614\/\" rel=\"nofollow noopener\" target=\"_blank\">Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial<\/a><br \/>Nordanstig J, James S, Andersson M, Andersson M, Delle M, Engstr\u00f6m J, Fransson T, Gillgren P, Hilbertson A, H\u00f6rer TM, Jacobsson E, Kragsterman B, Lindb\u00e4ck J, Lindgren H, Ludwigs K, Mellander S, Nelz\u00e9n O, Olin R, Sigvant B, Skoog P, Starck J, Tegler G, Thorbj\u00f8rnsen K, Truedson M, Wahlgren CM, Wallinder J, \u00d6jersj\u00f6 A, Falkenberg M; SWEDEPAD trial investigators. Lancet. 2025 Sep 13;406(10508):1115-1127. doi: 10.1016\/S0140-6736(25)01584-3. Epub 2025 Aug 31. PMID: 40902614.<\/p>\n","protected":false},"excerpt":{"rendered":"Vanlig behandling \u00e4r att vidga blodk\u00e4rlen med en ballong, ibland med hj\u00e4lp av ett litet metalln\u00e4t (stent). P\u00e5&hellip;\n","protected":false},"author":2,"featured_media":42439,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69],"tags":[113,112,34,31,33,32,30],"class_list":{"0":"post-42438","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-halsa","8":"tag-halsa","9":"tag-health","10":"tag-se","11":"tag-svenska","12":"tag-sverige","13":"tag-sweden","14":"tag-swedish"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/42438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=42438"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/42438\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/42439"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=42438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=42438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=42438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}